RT Journal Article SR Electronic T1 Recent developments in the treatment of small cell lung cancer JF European Respiratory Review JO EUROPEAN RESPIRATORY REVIEW FD European Respiratory Society SP 210079 DO 10.1183/16000617.0079-2021 VO 30 IS 161 A1 Birgitta I. Hiddinga A1 Jo Raskin A1 Annelies Janssens A1 Patrick Pauwels A1 Jan P. Van Meerbeeck YR 2021 UL http://err.ersjournals.com/content/30/161/210079.abstract AB Small cell lung cancer (SCLC) comprises about 15% of all lung cancers. It is an aggressive disease, with early metastasis and a poor prognosis. Until recently, SCLC treatment remained relatively unchanged, with chemotherapy remaining the cornerstone of treatment. In this overview we will highlight the recent advances in the field of staging, surgery, radiotherapy and systemic treatment. Nevertheless, the prognosis remains dismal and there is a pressing need for new treatment options. We describe the progress that has been made in systemic treatment by repurposing existing drugs and the addition of targeted treatment. In recent years, immunotherapy entered the clinic with high expectations of its role in the treatment of SCLC. Unravelling of the genomic sequence revealed new possible targets that may act as biomarkers in future treatment of patients with SCLC. Hopefully, in the near future, we will be able to identify patients who may benefit from targeted therapy or immunotherapy to improve prognoses.Advances in radiotherapy, targeted treatment and immunotherapy are limited. Progress in treatment options are needed for the treatment of SCLC. Exome sequencing to identify targetable biomarkers could select patients who would benefit from certain therapies. https://bit.ly/3e7ATJ4